• Prevention of Nausea and Vomiting After Laparoscopic Sleeve Gastrectomy: Are We Doing Enough?

    The worldwide obesity epidemic has led to an increase in the number of bariatric procedures for treatment. Currently, the most commonly performed bariatric surgical operation in the United States is the laparoscopic sleeve gastrectomy (LSG). The risk of postoperative nausea and vomiting (PONV) is exceptionally high following the LSG: as much as 65%. Anesthesia providers should be mindful of this elevated risk and stay up to date on evidence-based techniques that help to mitigate the incidence of PONV related to this specific procedure. The purposes of this clinical review are to increase provider awareness of the PONV risk following LSG and to examine methods for improving PONV outcomes for this population.

    Bariatric surgery, laparoscopic sleeve gastrectomy, postoperative nausea and vomiting.

    The World Health Organization notes that there are nearly 2 billion adults who are either overweight or obese worldwide.1 Current trends show an increase in the prevalence of obesity in almost every nation.2 The Centers for Disease Control and Prevention estimate that more than 93 million Americans, or about 40% of the population, are clinically obese.3 This widespread obesity has led to an increasing number of bariatric surgeries, which are procedures aimed at reducing obesity and its associated comorbidities.4 In the United States the estimated number of bariatric procedures performed rose from 158,000 in 2011 to 228,000 in 20175 (Figure 1*). In 2017 the laparoscopic sleeve gastrectomy (LSG) accounted for nearly 60% of all bariatric surgeries.5

    Although the LSG is safe and efficacious, postoperative nausea and vomiting (PONV) is abundantly common and problematic. Postoperative nausea and vomiting is more likely after LSG than after other bariatric procedures, with as many as 65% of patients experiencing PONV within the first 24 hours.6 Not only is PONV an unpleasant experience but also a multitude of complications can jeopardize the safety and welfare of patients. Among the more common problems are dehydration and electrolyte imbalances.7 During the vomiting event patients can experience aspiration, increased intracranial and intraocular pressures, wound dehiscence, and esophageal rupture.7 In addition, nausea and vomiting are the most common reasons for hospital readmission following bariatric surgery, and this leads to significant increases in healthcare expenditures.8

    As anesthesia providers, we aspire to provide safe care that extends well into the postoperative period without the occurrence of troublesome complications like PONV. Attaining these favorable results can be especially challenging after bariatric surgery. In people with morbid obesity, mask ventilation and intubation can be exceptionally difficult; hence, a thorough preoperative airway assessment is critical.9,10 Airway and soft-tissue obstruction are likely, because the incidence of obstructive sleep apnea and obstructive sleep-related breathing disorders in bariatric surgery candidates can be as high as 70%.11 These patients commonly present with multiple chronic conditions such as diabetes, fatty liver, and hypertension. In addition, they are more likely to have underlying cardiovascular disease.12 These comorbidities, along with associated risks related to body habitus in patients who are morbidly obese, necessitate an abundance of vigilance. Also, the anesthesia provider must be mindful of the likelihood for postoperative issues such as PONV and be prepared to act in the event of their occurrence.

    The purpose of this clinical review was twofold: first, to increase nurse anesthetists’ awareness of the increased incidence of PONV after LSG and second, to present evidence-based, alternative anesthetic approaches to decrease PONV in patients undergoing LSG. A literature search of the past 5 years was completed using the National Center for Biotechnology Information (NCBI) database. The search terms of surgery, bariatric, anesthesia, postoperative nausea, and/or postoperative vomiting yielded 30 articles. After discarding duplicates and examining reference lists of the selected articles, the authors reviewed 38 articles.

    Laparoscopic Sleeve Gastrectomy

    Since 1994, when Wittgrove and colleagues13 performed the first laparoscopic Roux-en-Y gastric bypass procedure, hundreds of thousands of minimally invasive bariatric operations have been conducted for the treatment of morbid obesity. Subsequently, other bariatric surgical options have been introduced, including the laparoscopic adjustable gastric band and the LSG.

    Although the laparoscopic adjustable gastric band was popular a decade ago, the LSG has now become the most common bariatric procedure in the United States5 (Figure 2*). The first LSG procedure was completed in 2000 by Ren et al.14 With the LSG, the stomach is downsized substantially to create a tubular structure that limits food consumption15 (Figure 3*). Compared with other bariatric operations, the LSG is simple and cost-effective, and it eliminates the need for gastrointestinal tract disruption.16,17 In addition to a drastic reduction in excess body weight, the long-term effects of the LSG procedure include decreases in hemoglobin A1c levels in patients with diabetes, lower Framingham scores for cardiovascular risk, and reduced blood pressure in patients with hypertension.18,19

    Despite its numerous beneficial attributes, the LSG results in an alarmingly high percentage of PONV compared with other forms of bariatric surgery.20 In fact, in one study PONV occurred in almost 60% of patients undergoing LSG compared with 19% in those undergoing laparoscopic Roux-en-Y gastric bypass.20

    Risk Factors for Postoperative Nausea and Vomiting

    Consideration of patient-related risk factors for PONV among those undergoing LSG is vital. These risks include age (primarily < 50 years), nonsmoking status, and a history of PONV or motion sickness.21 Perhaps the most influential patient-related risk factor is female gender; as many as 78% of female LSG recipients experience PONV within the first 24 hours after surgery compared with 26% of male patients.6,22

    Scientists and investigators have studied PONV for decades, but its complex etiology and pathophysiology have been an elusive and puzzling paradox.7 It is important to remember that there are several neurotransmitters responsible for producing an emetogenic response. These neurotransmitters include acetylcholine, serotonin, dopamine, histamine, and neurokinin-1.7 Fortunately, selected pharmacologic agents can be used to inhibit the action of these neurotransmitters and thereby reduce the stimuli that lead to nausea and vomiting.

    Additionally, understanding the anatomical origins of nausea and vomiting may lead to a better understanding of why LSG recipients are vulnerable to PONV. There are 4 pathways to the nucleus tractus solitarii in the hindbrain that activate vomiting.21 These pathways include (1) the afferent vagal nerve fibers from the gastrointestinal tract itself, (2) vestibular stimulation, (3) the area postrema in the medulla oblongata, and (4) the forebrain. Because the LSG involves gastric manipulation and incisions through afferent branches of the vagus nerve, it is hypothesized that stimulation of those nerve fibers is responsible for increasing the incidence of PONV after LSG.6,21 This risk may be increased because the manipulation of the procedure causes the release of 5-hydroxytryptamine from enterochromaffin cells in the stomach.23

    In addition to the anatomical aspects and numerous patient-related risks, there are several critical anesthesia-related elements that are also responsible for PONV. Among those are the use of postoperative opioids, inhalational anesthetics, and nitrous oxide, which have all been linked to inducing nausea and vomiting in the postoperative period.24

    Opioids. The perioperative and postoperative administration of opioids commonly used in anesthesia practice increases the likelihood of PONV.6,21,22,24 In one study 7 of 10 patients receiving postoperative rescue opioid analgesics experienced PONV compared with 44% who did not receive opioids for postoperative pain control.6 In addition to PONV, opioids carry a multitude of other deleterious side effects, including delayed gastric motility, depressed respirations, airway obstruction, and drowsiness, further complicating the postoperative period for this high-risk group.25

    Inhalational Anesthetics. Although opioids play a role in PONV, the use of inhalational anesthetics is also an important anesthesia-related risk factor.24 Patients undergoing total intravenous anesthesia (TIVA) experience significantly less postoperative severe nausea and retching compared with a classic inhalational balanced technique.26 Researchers compared the use of desflurane, a commonly used inhaled vapor, with an intravenous (IV)-only regimen consisting of propofol and dexmedetomidine for patients undergoing LSG.26 The TIVA group experienced a shorter duration in the postanesthesia care unit (PACU), thus indicating that the administration of a propofol-based TIVA was likely more beneficial in reducing PONV in the immediate postoperative period. In addition, there was a decreased need for rescue analgesia and ondansetron for PONV.26

    Reducing Postoperative Nausea and Vomiting After Laparoscopic Sleeve Gastrectomy

    Opioid-Free Anesthesia and Adjunctive Therapies. The relationship between opioid administration and PONV is apparent when opioid use is omitted. In fact, the rate of PONV was reduced by nearly 20% for patients receiving opioid-free anesthesia during laparoscopic bariatric surgery compared with a balanced anesthetic with triple-antiemetic therapy.20 Postoperative opioid administration is problematic, and these medications should be given judiciously.6,24

    For bariatric surgery, employing a nonopioid multimodal analgesic approach can be advantageous. Multimodal analgesia involves the administration of 2 or more analgesic medications with differing mechanisms of action to reduce opioid use, further minimizing the risk of PONV.27 Examples of these analgesics include acetaminophen, nonsteroidal anti-inflammatory drugs, N-methyl d-aspartate (NMDA) antagonists, α2 agonists, and gabapentinoids.

    Dexmedetomidine, an α2 agonist, provides an opioid-sparing effect in patients undergoing laparoscopic bariatric surgery and decreases the risk of PONV and postoperative shivering.28,29 When dexmedetomidine is administered during the intraoperative period as an IV infusion, inhalational agent requirements are reduced by approximately 20%.30,31 Reductions in propofol and fentanyl dosages are also observed when dexmedetomidine is a component of TIVA. Dexmedetomidine also decreases rescue analgesic needs in the PACU, further reducing the need for nausea-inducing opioids.30

    Another approach is an intraoperative lidocaine infusion, which produces a similar opioid-sparing effect to dexmedetomidine and is a cost-effective option.32 Systemic lidocaine provides analgesia, has anti-inflammatory properties, and promotes gastrointestinal tract motility, making it beneficial for this population.33

    Two other medications may also be helpful in decreasing PONV. Gabapentin plays a unique role as part of a multimodal regimen by decreasing opioid requirements and lowering the overall risk of PONV.34 Gabapentin works by binding to calcium channels, preventing the release of excitatory neurotransmitters responsible for nociceptive pain. When taken orally before LSG, gabapentin delays the need for postoperative oxycodone and reduces the overall 12-hour opioid requirement.35 Ketamine, an NMDA-receptor antagonist and µ-, δ-, and κ-opioid agonist, provides profound analgesia and is ideal for patients undergoing bariatric surgery because it promotes airway patency and respiratory drive in the postoperative period.36

    A commonly used analgesic, acetaminophen, is a beneficial adjunct. Acetaminophen is inexpensive, comes in both IV and oral formulations, and is beneficial for pain management.24 Acetaminophen works centrally and peripherally to relieve pain with minimal side effects.27 The IV formulation of acetaminophen should be used because of impaired gastric absorption following surgery and the possible intolerance to oral medications in the postoperative period.27

    Finally, neuromuscular blockade reversal with sugammadex demonstrates a mild reduction in PONV in the early postoperative period. In addition, less pain is experienced in the PACU compared with traditional neostigmine reversal.37

    Various forms of local and regional anesthesia have also been studied. Laparoscopic trocar site infiltration with bupivacaine provides a level of analgesia similar to epidural analgesia and is significantly superior to IV pain medications.38 In a study comparing postoperative narcotic requirements between patients receiving a transversus abdominus plane (TAP) block with liposomal bupivacaine and a standard patient-controlled analgesia (PCA) regimen with IV analgesia, the TAP block group received significantly fewer narcotics postoperatively compared with the PCA group.39 People in the PCA group were more likely to experience immediate postoperative nausea and subsequently required rescue antiemetic treatment. When possible, anesthesia providers should minimize the risk of PONV by using regional techniques.

    Enhanced Recovery After Surgery Protocols. Enhanced Recovery After Surgery (ERAS) protocols developed for bariatric surgery improve postoperative outcomes by decreasing opioid requirements following laparoscopic bariatric surgery, as well as reducing postdischarge emergency department visits.40,41 The ERAS protocols incorporate evidence-based multimodal analgesia techniques to optimize patient outcomes. In one ERAS protocol study, patients were discharged from the hospital sooner, reported lower pain scores, and required fewer opioids compared with patients who did not use ERAS protocols.40 As prospective evidence is introduced, the evolution of ERAS protocols may further enhance anesthesia care for patients undergoing LSG.

    Antiemetic Therapy. The 2014 consensus guidelines for PONV management provide detailed instruction on PONV prophylaxis according to the latest evidence-based data.24 For this review, only literature about antiemetics that were specific to patients undergoing the LSG will be discussed.

    The 5-hydroxytryptamine antagonist class includes ondansetron, one of the most popular and studied antiemetics. Ondansetron, 4 mg given IV, reduces PONV by 25% and is more effective at preventing vomiting than at preventing nausea.24 The 5-hydroxytryptamine antagonist group works in the chemoreceptor trigger zone, located in the area postrema and are most effective when given at the end of the procedure.7

    Aprepitant, a neurokinin-1 inhibitor, delays the onset and overall occurrence of vomiting following laparoscopic bariatric surgery.42 With a 40-hour half-life, the duration of action of aprepitant extends nearly 2 days into the postoperative period. Compared with ondansetron, aprepitant was as effective as ondansetron during the first 24 hours following surgery and more effective than ondansetron in the initial 24 to 48 hours, with minimal adverse effects.42

    Corticosteroids, most commonly dexamethasone, for PONV prophylaxis reduce the incidence of PONV by 25%.21 Controversy exists related to the use of any corticosteroid in patients with diabetes. This is due to the possibility of postoperative hyperglycemia, delayed wound healing, and infection.24 Additional studies are needed to confirm whether the risks outweigh the benefits of corticosteroid use in patients undergoing LSG.

    Butyrophenones, which include droperidol and haloperidol, are beneficial for PONV prophylaxis. Haloperidol, 0.5 to 2 mg, given either intramuscularly or IV, may reduce PONV without sedation or cardiac arrhythmias.24 It is important to note that haloperidol is not approved by the US Food and Drug Administration for IV administration as an antiemetic agent.

    Minimizing PONV following LSG is most successful when a multimodal approach with antiemetic medications is used rather than just a single drug.21,43 In one study a 63% reduction of PONV was seen when patients were given prophylactic triple antiemetic therapy using haloperidol, ondansetron, and dexamethasone vs ondansetron alone.43 Those 3 antiemetics also reduced postoperative morphine consumption nearly twofold compared with monotherapy with ondansetron.


    Discovering the perfect approach for PONV prevention after LSG is an ambitious task that continues to present challenges for the anesthesia care team, and more research is needed to develop better protocols. Research has shown that outcomes are improved when opioids and inhalational agents are kept to a minimum. Although opioids are often a component in the treatment of acute surgical pain, adjunctive agents can decrease the total opioid dose as well as minimize undesirable side effects, which may be magnified by the multiple comorbidities associated with obesity.

    As the LSG becomes a more attractive treatment option for weight loss, diabetes remission, blood pressure reduction, and improvement in overall cardiovascular health, anesthesia providers should be aware of the procedure’s emetogenic potential and stay up to date on strategies to improve care, outcomes, and patient satisfaction. Because of the relative newness of the LSG operation, questions remain about the direction anesthesia providers must take. Does the future of anesthesia for bariatric surgery focus on the use of opioid-free techniques and incorporate more regional techniques? Should independent PONV treatment recommendations be made especially for LSG procedures? Until these questions are answered, anesthesia professionals should strive to increase their knowledge of the numerous PONV risks associated with LSG and incorporate evidence-based protocols into their routine.


    1. World Health Organization. Obesity and overweight. http://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight. February 16, 2018. Accessed October 7, 2018.

    2. Abarca-Gómez L, Abdeen ZA, Hamid ZA, et al; NCD Risk Factor Collaboration. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627-2642. doi:10.1016/S0140-6736(17)32129-3

    3. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015-2016. NCHS data brief, no 288. Hyattsville, MD: National Center for Health Statistics; 2017. https://www.ncbi.nlm.nih.gov/pubmed/29155689

    4. Weiner RA. Indications and principles of the metabolic surgery [German]. Surgeon. 2010;81(4):379-396. doi:10.1007/s00104-009-1859-9

    5. American Society for Metabolic and Bariatric Surgery. Estimate of bariatric surgery numbers, 2011-2018. https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers. Updated June 2018. Accessed October 9, 2018.

    6. Halliday TA, Sundqvist J, Hultin M, Walldén J. Post-operative nausea and vomiting in bariatric surgery patients: an observational study. Acta Anaesthesiol Scand. 2017;61(5):471-479. doi:10.1111/aas.12884

    7. Blackburn J, Spencer R. Postoperative nausea and vomiting. Anaesth Intensive Care Med. 2015;16(9):452-456. doi:10.1016/j.mpaic.2015.06.020

    8. Berger E, Huffman K, Fraker T, et al. Prevalence and risk factors for bariatric surgery readmissions: findings from 130,007 admissions in the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program. Ann Surg. 2018;267(1):122-131. doi:10.1097/SLA.0000000000002079

    9. Bazurro S, Ball L, Pelosi P. Perioperative management of obese patient. Curr Opin Crit Care. 2018;24(6):560-567. doi:10.1097/MCC.0000000000000555

    10. Soleimanpour H, Safari S, Sanaie S, Nazari M, Alavian SM. Anesthetic considerations in patients undergoing bariatric surgery: a review article. Anesth Pain Med. 2017;7(4):e57568. doi:10.5812/aapm.57568

    11. Frey WC, Pilcher J. Obstructive sleep-related breathing disorders in patients evaluated for bariatric surgery. Obes Surg. 2003;13(5):676-683. doi:10.1381/096089203322509228

    12. Ferreira LM. Obesity comorbidities: what you need to know. Obesity News Today. https://obesitynewstoday.com/obesity-comorbidities/. Accessed October 22, 2018.

    13. Wittgrove AC, Clark GW, Tremblay LJ. Laparoscopic gastric bypass, Roux-en-Y: preliminary report of five cases. Obes Surg. 1994;4(4):353-357. doi:10.1381/096089294765558331

    14. Ren CJ, Patterson E, Gagner M. Early results of laparoscopic biliopancreatic diversion with duodenal switch: a case series of 40 consecutive patients. Obes Surg. 2000;10(6):514-523. doi:10.1381/096089200321593715

    15. American Society for Metabolic and Bariatric Surgery. Metabolic and bariatric surgery. https://asmbs.org/resources/metabolic-and-bariatric-surgery. Published November 2013. Accessed October 9, 2018.

    16. Gumbs AA, Gagner M, Dakin G, Pomp A. Sleeve gastrectomy for morbid obesity. Obes Surg. 2007;17(7):962-969. doi:10.1007/s11695-007-9151-x

    17. Kumar SB, Hamilton BC, Wood SG, Rogers SJ, Carter JT, Lin MY. Is laparoscopic sleeve gastrectomy safer than laparoscopic gastric bypass? A comparison of 30-day complications using the MBSAQIP data registry. Surg Obes Relat Dis. 2018;14(3):264-269. doi:10.1016/j.soard.2017.12.011

    18. Samson R, Milligan G, Lewine E, et al. Effect of sleeve gastrectomy on hypertension. J Am Soc Hypertens. 2018;12(11):e19-e25. doi:10.1016/j.jash.2018.09.007

    19. Abbatini F, Capoccia D, Casella G, Soricelli E, Leonetti F, Basso N. Long-term remission of type 2 diabetes in morbidly obese patients after sleeve gastrectomy. Surg Obes Relat Dis. 2013;9(4):498-502. doi:10.1016/j.soard.2012.09.003

    20. Ziemann-Gimmel P, Goldfarb AA, Koppman J, Marema RT. Opioid-free total intravenous anaesthesia reduces postoperative nausea and vomiting in bariatric surgery beyond triple prophylaxis. Br J Anaesth. 2014;112(5):906-911. doi:10.1093/bja/aet551

    21. Horn CC, Wallisch WJ, Homanics GE, Williams JP. Pathophysiological and neurochemical mechanisms of postoperative nausea and vomiting. Eur J Pharmacol. 2014;722:55-66. doi:10.1016/j.ejphar.2013.10.037

    22. Apfel CC, Heidrich FM, Jukar-Rao S, et al. Evidence-based analysis of risk factors for postoperative nausea and vomiting. Br J Anaesth. 2012;109(5):742-753. doi:10.1093/bja/aes276

    23. Bataille A, Letourneulx J-F, Charmeau A, et al. Impact of a prophylactic combination of dexamethasone-ondansetron on postoperative nausea and vomiting in obese adult patients undergoing laparoscopic sleeve gastrectomy during closed-loop propofol-remifentanil anaesthesia: a randomised double-blind placebo-controlled study. Eur J Anaesthesiol. 2016;33(12):898-905. doi:10.1097/EJA.0000000000000427

    24. Gan TJ, Diemunsch P, Habib AS, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2014;118(1):85-113. doi:10.1213/ANE.0000000000000002

    25. Royal College of Anaesthetists. Side effects of opioids. https://www.rcoa.ac.uk/faculty-of-pain-medicine/opioids-aware/clinical-use-of-opioids/opioid-side-effects. Updated 2019. Accessed March 8, 2019.

    26. Elbakry A-E, Sultan W-E, Ibrahim E. A comparison between inhalational (desflurane) and total intravenous anaesthesia (propofol and dexmedetomidine) in improving postoperative recovery for morbidly obese patients undergoing laparoscopic sleeve gastrectomy: a double-blinded randomized controlled trial. J Clin Anesth. 2018;45:6-11. doi:10.1016/j.jclinane.2017.12.001

    27. Song K, Melroy MJ, Whipple OC. Optimizing multimodal analgesia with intravenous acetaminophen and opioids in postoperative bariatric patients. Pharmacotherapy. 2014;34(suppl 1):14S-21S. doi:10.1002/phar.1517

    28. Singh PM, Panwar R, Borle A, Mulier JP, Sinha A, Goudra B. Perioperative analgesic profile of dexmedetomidine infusions in morbidly obese undergoing bariatric surgery: a meta-analysis and trial sequential analysis. Surg Obes Relat Dis. 2017;13(8):1434-1446. doi:10.1016/j.soard.2017.02.025

    29. Ramaswamy S, Wilson JA, Colvin L. Non-opioid-based adjuvant analgesia in perioperative care. Continu Educ Anaesth Crit Care Pain. 2013;13(5):152-157. doi:10.1093/bjaceaccp/mkt012

    30. Tufanogullari B, White PF, Peixoto MP, et al. Dexmedetomidine infusion during laparoscopic bariatric surgery: the effect on recovery outcome variables. Anesth Analg. 2008;106(6):1741-1748. doi:10.1213/ane.0b013e318172c47c

    31. Bakhamees HS, El-Halafawy YM, El-Kerdawy HM, Gouda NM, Altemyatt S. Effects of dexmedetomidine in morbidly obese patients undergoing laparoscopic gastric bypass. Middle East J Anaesthesiol. 2007;19(3):537-551.

    32. Sherif AA, Elsersy HE. The impact of dexmedetomidine or xylocaine continuous infusion on opioid consumption and recovery after laparoscopic sleeve gastrectomy. Minerva Anestesiol. 2017;83(12):1274-1282. doi:10.23736/S0375-9393.17.11855-9

    33. Eipe N, Gupta S, Penning J. Intravenous lidocaine for acute pain: an evidence-based clinical update. BJA Educ. 2016;16(9):292-298. doi:10.1093/bjaed/mkw008

    34. Grant M, Lee HW, Page A, Hobson D, Wick E, Wu C. The effect of preoperative gabapentin on postoperative nausea and vomiting: a meta-analysis. Anesth Analg. 2016;122(4):976-985. doi:10.1213/ANE.0000000000001120

    35. Rupniewska-Ladyko A, Malec-Milewska M, Kraszewska E, Pirozynski M. Gabapentin before laparoscopic sleeve gastrectomy reduces postoperative oxycodone consumption in obese patients: a randomized double-blind placebo-controlled trial. Minerva Anestesiol. 2017;84(5):565-571. doi:10.23736/S0375-9393.17.12194-2

    36. Aronsohn J, Orner G, Palleschi G, Gerasimov M. Opioid-free total intravenous anesthesia with ketamine as part of an enhanced recovery protocol for bariatric surgery patients with sleep disordered breathing. J Clin Anesth. 2019;52:65-66. doi:10.1016/j.jclinane.2018.09.014

    37. Castro DS Jr, Leao P, Borges S, Gomes L, Pacheco M, Figueiredo P. Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: a randomized trial. Surg Laparosc Endosc Percutan Tech. 2014;24(5):420-423. doi:10.1097/SLE.0000000000000049

    38. Ruiz-Tovar J, Munoz JL, Gonzalez J, et al. Postoperative pain after laparoscopic sleeve gastrectomy: comparison of three analgesic schemes (isolated intravenous analgesia, epidural analgesia associated with intravenous analgesia and port-sites infiltration with bupivacaine associated with intravenous analgesia). Surg Endosc. 2017;31(1):231-236. doi:10.1007/s00464-016-4961-3

    39. Bhakta A, Glotzer O, Ata A, Tafen M, Stain SC, Singh PT. Analgesic efficacy of laparoscopic-guided transverse abdominis plane block using liposomal bupivacaine in bariatric surgery. Am J Surg. 2018;215(4):643-646. doi:10.1016/j.amjsurg.2017.09.006

    40. King AB, Spann MD, Jablonski P, Wanderer JP, Sandberg WS, McEvoy MD. An enhanced recovery program for bariatric surgical patients significantly reduces perioperative opioid consumption and postoperative nausea. Surg Obes Relat Dis. 2018;14(6):849-856. doi:10.1016/j.soard.2018.02.010

    41. Lam J, Suzuki T, Bernstein D, et al. An ERAS protocol for bariatric surgery: is it safe to discharge on post-operative day 1? Surg Endosc. 2019;33(2):580-586. doi:10.1007/s00464-018-6368-9

    42. Sinha A, Singh PM, Williams NW, Ochroch EA, Goudra BG. Aprepitant’s prophylactic efficacy in decreasing postoperative nausea and vomiting in morbidly obese patients undergoing bariatric surgery. Obes Surg. 2014;24(2):225-231. doi:10.1007/s11695-013-1065-1

    43. Benevides M, de Souza Oliveira SS, de Aguilar-Nascimento JE. The combination of haloperidol, dexamethasone, and ondansetron for the prevention of postoperative nausea and vomiting in laparoscopic sleeve gastrectomy: a randomized double-blind trial. Obes Surg. 2013;23(9):1389-1396. doi:10.1007/s11695-013-0923-1


    Kerry L. Varner, MSNA, CRNA, is employed by Southeast Health in Dothan, Alabama. Email: klvarner@crimson.ua.edu.

    Alice L. March, PhD, RN, FNP, CNE, is a professor at the University of Alabama’s Capstone College of Nursing in Tuscaloosa, Alabama. Email: almarch@ua.edu.


    The authors have declared no financial relationships with any commercial entity related to the content of this article. The authors did discuss off-label use within the article. Disclosure statements are available for viewing upon request.


    Please click here for a PDF of this article.


  • Share